{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:19:36Z","timestamp":1793110776416,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40290-023-00462-2","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T12:44:21Z","timestamp":1676637861000},"page":"153-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Presentations of Drug-Induced Hyperprolactinaemia: A Literature Review"],"prefix":"10.1007","volume":"37","author":[{"given":"Daniela R.","family":"Junqueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-9342","authenticated-orcid":false,"given":"Dimitri","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Y.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Casa\u00f1as i Comabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"1","key":"462_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/cen.13156","volume":"86","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 2017;86(1):60\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"462_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273\u201388.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"462_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265\u201373.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"462_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrendo.2015.36","volume":"11","author":"V Bernard","year":"2015","unstructured":"Bernard V, Young J, Chanson P, Binart N. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015;11(5):265\u201375.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"462_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/BF03345805","volume":"35","author":"M Galdiero","year":"2012","unstructured":"Galdiero M, Pivonello R, Grasso LFS, Cozzolino A, Colao A. Growth hormone, prolactin, and sexuality. J Endocrinol Investig. 2012;35(8):782\u201394.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"462_CR6","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1530\/JME-13-0220","volume":"52","author":"ND Horseman","year":"2014","unstructured":"Horseman ND, Gregerson KA. Prolactin actions. J Mol Endocrinol. 2014;52(1):R95-106.","journal-title":"J Mol Endocrinol"},{"issue":"13","key":"462_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","volume":"362","author":"A Klibanski","year":"2010","unstructured":"Klibanski A. Clinical practice Prolactinomas. N Engl J Med. 2010;362(13):1219\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"462_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4274\/jcrpe.galenos.2018.2018.0206","volume":"11","author":"E Eren","year":"2019","unstructured":"Eren E, TorelErgur A, Isguven SP, CelebiBitkin E, Berberoglu M, Siklar Z, et al. Clinical and laboratory characteristics of hyperprolactinemia in children and adolescents: national survey. J Clin Res Pediatr Endocrinol. 2019;11(2):149\u201356.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"462_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0269881114562090","volume":"29","author":"SL Young","year":"2015","unstructured":"Young SL, Taylor M, Lawrie SM. \u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29(4):353\u201362.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"462_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R Jr, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Investig. 2008;31(5):436\u201344.","journal-title":"J Endocrinol Investig"},{"key":"462_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s11102-021-01189-6","volume":"25","author":"LE Castellanos","year":"2022","unstructured":"Castellanos LE, Gutierrez C, Smith T, Laws ER, Iorgulescu JB. Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organisation classification. Pituitary. 2022;25:201\u20139.","journal-title":"Pituitary"},{"key":"462_CR12","first-page":"1050","volume-title":"Medication-induced hyperprolactinemia. Mayo Clinic Proceedings","author":"ME Molitch","year":"2005","unstructured":"Molitch ME. Medication-induced hyperprolactinemia. Mayo Clinic Proceedings. Amsterdam: Elsevier; 2005. p. 1050\u20137."},{"issue":"4","key":"462_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.1116","volume":"25","author":"S Madhusoodanan","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics\u2014a review. Hum Psychopharmacol. 2010;25(4):281\u201397.","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"462_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000499694","volume":"109","author":"L Vilar","year":"2019","unstructured":"Vilar L, Vilar CF, Lyra R, da Conceicao FM. Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology. 2019;109(1):7\u201319.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"462_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0188-4409(02)00403-4","volume":"33","author":"M Atmaca","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici O. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33(6):562\u20135.","journal-title":"Arch Med Res"},{"issue":"2","key":"462_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0020-7292(93)90326-R","volume":"43","author":"AS Karaman","year":"1993","unstructured":"Karaman AS, Uran B, Erler A. Serum prolactin levels in postpill amenorrheic patients. Int J Gynaecol Obstet. 1993;43(2):177\u201380.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"462_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"462_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","volume":"64","author":"MS Lee","year":"2010","unstructured":"Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomised, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci. 2010;64(1):19\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"462_CR19","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","volume":"32","author":"ML Lu","year":"2008","unstructured":"Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978\u201381.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"462_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/JCP.0000000000000607","volume":"36","author":"SC Man","year":"2016","unstructured":"Man SC, Li XB, Wang HH, Yuan HN, Wang HN, Zhang RG, et al. Peony-glycyrrhiza decoction for antipsychotic-related hyperprolactinemia in women with schizophrenia: a randomised controlled trial. J Clin Psychopharmacol. 2016;36(6):572\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"462_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.psychres.2015.12.033","volume":"237","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Yang F, Li C, Guo Q, Wen H, Zhu S, et al. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone. Psychiatry Res. 2016;237:83\u20139.","journal-title":"Psychiatry Res"},{"key":"462_CR22","first-page":"549","volume":"11","author":"F Ranjbar","year":"2015","unstructured":"Ranjbar F, Sadeghi-Bazargani H, Khams PN, Arfaie A, Salari A, Farahbakhsh M. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatr Dis Treat. 2015;11:549\u201355.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"462_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, Shin JGK, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404\u201310.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"462_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0000000000000175","volume":"39","author":"HW Yoon","year":"2016","unstructured":"Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol. 2016;39(6):288\u201394.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"462_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/JCP.0b013e318172473c","volume":"28","author":"HN Yuan","year":"2008","unstructured":"Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol. 2008;28(3):264\u201370.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"462_CR26","first-page":"154","volume":"7","author":"Z Barszcz","year":"2007","unstructured":"Barszcz Z, Mucha S, Rabe-Jablonska J. Co-medication with psychotropic drugs, including antipsychotic drugs, and bromocriptine: changes in clinical signs of hyperprolactinaemia and prolactin level. Psychiatria i Psychologia Kliniczna. 2007;7(3):154\u201364.","journal-title":"Psychiatria i Psychologia Kliniczna."},{"issue":"2","key":"462_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/00016348009154630","volume":"59","author":"M Furuhjelm","year":"1980","unstructured":"Furuhjelm M, Rydner T, Carlstrom K. Hyperprolactinemia in cases of infertility and amenorrhea. Acta Obstet Gynecol Scand. 1980;59(2):137\u201341.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"462_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","volume":"26","author":"L Holzer","year":"2006","unstructured":"Holzer L, Eap CB. Risperidone-induced symptomatic hyperprolactinemia in adolescents. J Clin Psychopharmacol. 2006;26(2):167\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"462_CR29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1037\/a0033448","volume":"21","author":"CS Kalkavoura","year":"2013","unstructured":"Kalkavoura CS, Michopoulos I, Arvanitakis P, Theodoropoulou P, Dimopoulou K, Tzebelikos E, et al. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332\u201341.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"6","key":"462_CR30","first-page":"803","volume":"27","author":"M Kopecek","year":"2006","unstructured":"Kopecek M, Bares M, Horacek J, Mohr P. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. Neuroendocrinol Lett. 2006;27(6):803\u20136.","journal-title":"Neuroendocrinol Lett"},{"issue":"3\u20134","key":"462_CR31","first-page":"199","volume":"20","author":"K Melkersson","year":"1999","unstructured":"Melkersson K, Hulting AL, Hall K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrinol Lett. 1999;20(3\u20134):199\u2013204.","journal-title":"Neuroendocrinol Lett"},{"issue":"6","key":"462_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.4088\/JCP.v66n0614","volume":"66","author":"K Melkersson","year":"2005","unstructured":"Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry. 2005;66(6):761\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"462_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","volume":"49","author":"A Pollock","year":"1998","unstructured":"Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol. 1998;49(4):513\u20136.","journal-title":"Clin Endocrinol"},{"issue":"6","key":"462_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/cap.2011.0109","volume":"22","author":"Y Roke","year":"2012","unstructured":"Roke Y, Buitelaar JK, Boot AM, Tenback D, Van Harten PN. Risk of hyperprolactinemia and sexual side effects in males 10\u201320 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol. 2012;22(6):432\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"462_CR35","first-page":"457","volume":"86","author":"M Seppala","year":"1977","unstructured":"Seppala M, Lehtovirta P, Ranta T. Discordant patterns of hyperprolactinaemia and galactorrhoea in secondary amenorrhoea. Acta Endocrinol. 1977;86(3):457\u201363.","journal-title":"Acta Endocrinol"},{"issue":"12","key":"462_CR36","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2165\/11595660-000000000-00000","volume":"34","author":"T Trenque","year":"2011","unstructured":"Trenque T, Herlem E, Auriche P, Dram M. Serotonin reuptake inhibitors and hyperprolactinaemia: a case\/non-case study in the French pharmacovigilance database. Drug Saf. 2011;34(12):1161\u20136.","journal-title":"Drug Saf"},{"issue":"4","key":"462_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1439-0272.2008.00850.x","volume":"40","author":"MS Venetikou","year":"2008","unstructured":"Venetikou MS, Lambou T, Gisani D. Hyperprolactinaemia due to hypothalamic-pituitary disease or drug-induced in patients with erectile dysfunction. Andrologia. 2008;40(4):240\u20134.","journal-title":"Andrologia"},{"issue":"3","key":"462_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11055-018-0571-y","volume":"48","author":"OA Yunilainen","year":"2018","unstructured":"Yunilainen OA, Starostina EG, Dzeranova LK, Kudryashkina GN, Kessel\u2019man LG, Baranov PA, et al. Neuroleptic-associated hyperprolactinemia: clinical manifestations and effects on sexual function. Neurosci Behav Physiol. 2018;48(3):358\u201366.","journal-title":"Neurosci Behav Physiol"},{"issue":"2","key":"462_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4088\/JCP.v65n0207","volume":"65","author":"R Cavallaro","year":"2004","unstructured":"Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65(2):187\u201390.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"462_CR40","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0269881107082901","volume":"22","author":"A Mir","year":"2008","unstructured":"Mir A, Shivakumar K, Williamson RJ, McAllister V, O\u2019Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244\u201353.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"462_CR41","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/cap.2014.0130","volume":"25","author":"A Savitz","year":"2015","unstructured":"Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S. Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study. J Child Adolesc Psychopharmacol. 2015;25(7):548\u201357.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"462_CR42","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","volume":"33","author":"MZ Trives","year":"2013","unstructured":"Trives MZ, Llacer JMB, Escudero MAG, Pastor CJM. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33(4):538\u201341.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"462_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4103\/ijem.IJEM_89_18","volume":"22","author":"S Atluri","year":"2018","unstructured":"Atluri S, Sarathi V, Goel A, Boppana R, Shivaprasad C. Etiological profile of galactorrhoea. Indian J Endocrinol Metab. 2018;22(4):489\u201393.","journal-title":"Indian J Endocrinol Metab"},{"issue":"8","key":"462_CR44","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"CK Chen","year":"2010","unstructured":"Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"462_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2045125311426896","volume":"1","author":"Z Kotan","year":"2011","unstructured":"Kotan Z, Ertepe B, Akkaya C, Sarandol E, Ozkaya G, Kirli S. Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Ther Adv Psychopharmacol. 2011;1(6):189\u201396.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"462_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4103\/ijem.IJEM_515_16","volume":"21","author":"B Kulshreshtha","year":"2017","unstructured":"Kulshreshtha B, Pahuja I, Kothari D, Chawla I, Sharma N, Gupta S, et al. Menstrual cycle abnormalities in patients with prolactinoma and drug-induced hyperprolactinemia. Indian J Endocrinol Metab. 2017;21(4):545\u201350.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"462_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/13651500510014747","volume":"9","author":"BH Lee","year":"2005","unstructured":"Lee BH, Han CS, Kim KH, Kim YK. Treatment in risperidone-induced amenorrhoea. Int J Psychiatry Clin Pract. 2005;9(1):29\u201334.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"462_CR48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S0022-5347(17)38964-4","volume":"142","author":"MP Leonard","year":"1989","unstructured":"Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. J Urol. 1989;142(4):992\u20134.","journal-title":"J Urol"},{"issue":"2","key":"462_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/YIC.0000000000000063","volume":"30","author":"L Margari","year":"2015","unstructured":"Margari L, Matera E, Petruzzelli MG, Simone M, Lamanna AL, Pastore A, et al. Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. Int Clin Psychopharmacol. 2015;30(2):103\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"462_CR50","first-page":"737","volume":"37","author":"S Smith","year":"1992","unstructured":"Smith S. Neuroleptic-associated hyperprolactinemia: Can it be treated with bromocriptine? J Reprod Med Obstet Gynecol. 1992;37(8):737\u201340.","journal-title":"J Reprod Med Obstet Gynecol"},{"issue":"6","key":"462_CR51","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","volume":"32","author":"R Perez-Iglesias","year":"2012","unstructured":"Perez-Iglesias R, Mata I, Martinez-Garcia O, Garcia-Unzueta MT, Amado JA, Valdisan EM, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol. 2012;32(6):804\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"462_CR52","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","volume":"22","author":"FD Alosaimi","year":"2018","unstructured":"Alosaimi FD, Fallata EO, Abalhassan M, Alhabbad A, Alzain N, Alhaddad B, et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract. 2018;22(4):274\u201381.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"2","key":"462_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","volume":"28","author":"R Emsley","year":"2008","unstructured":"Emsley R, Medori R, Koen L, Oosthuisen PP, Niehaus DJH, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210\u20133.","journal-title":"J Clin Psychopharmacol"},{"key":"462_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","volume":"239","author":"YM Park","year":"2016","unstructured":"Park YM, Lee SH, Lee BH, Lee KY, Lee KS, Kang SG, et al. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study. Psychiatry Res. 2016;239:184\u20139.","journal-title":"Psychiatry Res"},{"key":"462_CR55","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.12659\/MSM.913759","volume":"24","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Tang Z, Ruan Y, Huang C, Wu J, Lu Z, et al. Prolactin and thyroid stimulating hormone (TSH) levels and sexual dysfunction in patients with schizophrenia treated with conventional antipsychotic medication: a cross-sectional study. Med Sci Monit. 2018;24:9136\u201343.","journal-title":"Med Sci Monit"},{"issue":"3","key":"462_CR56","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","volume":"31","author":"DL Kelly","year":"2006","unstructured":"Kelly DL, Conley RR. A randomised double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31(3):340\u20136.","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"462_CR57","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","volume":"31","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31(5):577\u201388.","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"462_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.pnpbp.2005.11.037","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):658\u201362.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"462_CR59","first-page":"639","volume":"40","author":"I Matsuoka","year":"1986","unstructured":"Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. Jpn J Psychiatry Neurol. 1986;40(4):639\u201346.","journal-title":"Jpn J Psychiatry Neurol"},{"issue":"1","key":"462_CR60","first-page":"1","volume":"100","author":"AN Andersen","year":"1982","unstructured":"Andersen AN, Schioler V, Hertz J, Bennett P. Effect of metoclopramide induced hyperprolactinaemia on the gonadotrophic response to oestradiol and LRH. Acta Endocrinol. 1982;100(1):1\u20139.","journal-title":"Acta Endocrinol"},{"key":"462_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2019.02.017","volume":"274","author":"SW During","year":"2019","unstructured":"During SW, Nielsen MO, Bak N, Glenthoj BY, Ebdrup BH. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2\/3 receptor blockade\u2014an exploratory study. Psychiatry Res. 2019;274:58\u201365.","journal-title":"Psychiatry Res"},{"key":"462_CR62","unstructured":"World Health Organisation. International Classification of Diseases 11th Revision (ICD-11). https:\/\/icd.who.int\/en [cited 2022 Feb 7]."},{"issue":"2","key":"462_CR63","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1176\/appi.psy.49.2.163","volume":"49","author":"N Ahuja","year":"2008","unstructured":"Ahuja N, Moorhead S, Lloyd AJ, Cole AJ. Antipsychotic-induced hyperprolactinemia and delusion of pregnancy. Psychosomatics. 2008;49(2):163\u20137.","journal-title":"Psychosomatics"},{"issue":"Pt 6","key":"462_CR64","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1177\/000456328602300603","volume":"23","author":"SL Jeffcoate","year":"1986","unstructured":"Jeffcoate SL, Bacon RR, Beastall GH, Diver MJ, Franks S, Seth J. Assays for prolactin: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem. 1986;23(Pt 6):638\u201351.","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"462_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1210\/jcem-53-1-109","volume":"53","author":"HV Lankford","year":"1981","unstructured":"Lankford HV, Blackard WG, Gardner DF, Tucker HS. Effects of thyrotropin-releasing hormone and metoclopramide in patients with phenothiazine-induced hyperprolactinemia. J Clin Endocrinol Metab. 1981;53(1):109\u201312.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-023-00462-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T19:08:17Z","timestamp":1681326497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-023-00462-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1007\/s40290-023-00462-2","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"22 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study\u00a0 was sponsored by Takeda Development Center Americas, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DB is a current and SYH is a former employee of Takeda Development Center Americas, Inc. and received stock or stock options at the time of study. Currently SYH is employed by Ironwood Pharmaceuticals. DRJ and CCiC provide consultancy support to Takeda Development Center Americas, Inc. as employees of Evidera.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Study analyzed anonymously using already published data: Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Study analysed anonymously using already published data: Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data presented is available in manuscript and\/or supplementary material.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DRJ, DB, SYH, and CCC led the research conceptualisation and methodology. DRJ led the data curation, formal analysis, investigation, project administration, and visualisation. She wrote the original draft and worked with all co-authors in reviewing and editing the final manuscript.\u00a0All authors reviewed and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}